Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
23 February, 2019 01:56 IST
Lupin launches generic Clobetasol propionate ointment in US
Source: IRIS | 10 Oct, 2018, 09.59AM
Comments  |  Post Comment

Pharma major Lupin announced the launch of Clobetasol Propionate Ointment USP 0.05%, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Clobetasol Propionate Ointment USP, 0.05% is the generic equivalent of Fougera Pharmaceuticals Inc.'s Temovate Ointment, 0.05%. It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Clobetasol Propionate Ointment USP 0.05% had annual sales of approximately USD 93.4 million in the US (IQVIA MAT June 2018).

Shares of the company gained Rs 13.7, or 1.58%, to trade at Rs 879.20. The total volume of shares traded was 23,154 at the BSE (9.49 a.m., Wednesday).



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Sector
Zydus Cadila receives final USFDA approvals for 2 drugs - 22-Feb-2019 10:43
Aarti Industries signs USD 125 mn multi-year deal - 20-Feb-2019 10:53
Glenmark to present data on Ryaltris at AAAAI 2019 - 20-Feb-2019 10:48
ABB bags train technologies order worth Rs 2.70 bn - 20-Feb-2019 10:30
Cipla, Wellthy Therapeutics announce partnership to offer digital therapeutics - 19-Feb-2019 10:58
Glenmark Pharma receives ANDA approval for Clobetasol propionate foam - 18-Feb-2019 10:45
L&T Construction secures contract for design and construction of major airport - 18-Feb-2019 10:42
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer